| scholarly article | Q13442814 |
| P356 | DOI | 10.1046/J.1365-2222.2003.01699.X |
| P698 | PubMed publication ID | 12956739 |
| P50 | author | Peter Valent | Q56697676 |
| P2093 | author name string | D Kraft | |
| R Valenta | |||
| W R Sperr | |||
| H Semper | |||
| V Niederberger | |||
| N Mothes | |||
| M Heinzkill | |||
| K J Drachenberg | |||
| M T Krauth | |||
| Y Majlesi | |||
| P2860 | cites work | A human monoclonal IgE antibody defines a highly allergenic fragment of the major timothy grass pollen allergen, Phl p 5: molecular, immunological, and structural characterization of the epitope-containing domain. | Q31815273 |
| Immunological mechanisms operative in allergen-specific immunotherapy | Q33643137 | ||
| The Th1/Th2 paradigm | Q34429440 | ||
| Safety, immunogenicity, and efficacy of Plasmodium falciparum repeatless circumsporozoite protein vaccine encapsulated in liposomes | Q40933066 | ||
| A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections | Q43650387 | ||
| A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines. | Q43812891 | ||
| Molecular characterization of human IgG monoclonal antibodies specific for the major birch pollen allergen Bet v 1. Anti-allergen IgG can enhance the anaphylactic reaction. | Q47895314 | ||
| PROPHYLACTIC INOCULATION AGAINST HAY FEVER | Q57255078 | ||
| Polarized TH1 responses by liposome-entrapped allergen and its potential in immunotherapy of allergic disorders | Q74452718 | ||
| Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system | Q74486539 | ||
| Allergenic activity of a major grass pollen allergen is elevated in the presence of nasal secretion | Q74490053 | ||
| P433 | issue | 9 | |
| P921 | main subject | antibody | Q79460 |
| vaccine | Q134808 | ||
| immunotherapy | Q1427096 | ||
| P304 | page(s) | 1198-1208 | |
| P577 | publication date | 2003-09-01 | |
| P1433 | published in | Clinical & Experimental Allergy | Q5133747 |
| P1476 | title | Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies | |
| P478 | volume | 33 |
| Q37625474 | A B Cell Epitope Peptide Derived from the Major Grass Pollen Allergen Phl p 1 Boosts Allergen-Specific Secondary Antibody Responses without Allergen-Specific T Cell Help |
| Q42713288 | A Fusion Protein Consisting of the Vaccine Adjuvant Monophosphoryl Lipid A and the Allergen Ovalbumin Boosts Allergen-Specific Th1, Th2, and Th17 Responses In Vitro |
| Q39343215 | A hybrid expressing genetically engineered major allergens of the Parietaria pollen as a tool for specific allergy vaccination |
| Q88964571 | A lipid A-based TLR4 mimetic effectively adjuvants a Yersinia pestis rF-V1 subunit vaccine in a murine challenge model |
| Q53006587 | A novel adjuvant complex, tyrosine-MPL, for prophylactic and therapeutic vaccines. |
| Q30768718 | A novel adjuvant-allergen complex, CBP-rFel d 1, induces up-regulation of CD86 expression and enhances cytokine release by human dendritic cells in vitro. |
| Q52846388 | A preventive immunization approach against insect bite hypersensitivity: Intralymphatic injection with recombinant allergens in Alum or Alum and monophosphoryl lipid A. |
| Q80156066 | A synthetic triacylated pseudo-dipeptide molecule promotes Th1/TReg immune responses and enhances tolerance induction via the sublingual route |
| Q46879563 | Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children |
| Q39151158 | Adjuvants for allergy immunotherapeutics. |
| Q38055323 | Adjuvants for allergy vaccines |
| Q57297464 | Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy: Is There a Future? |
| Q90181979 | Allergen Immunotherapy-Induced Immunoglobulin G4 Reduces Basophil Activation in House Dust Mite-Allergic Asthma Patients |
| Q36864947 | Allergen immunotherapy for allergic respiratory diseases |
| Q61814280 | Allergen-Specific Antibodies Regulate Secondary Allergen-Specific Immune Responses |
| Q37166041 | Allergen-specific IgG antibodies purified from mite-allergic patients sera block the IgE recognition of Dermatophagoides pteronyssinus antigens: an in vitro study |
| Q40006542 | Allergen-specific immunotherapy of allergy and asthma: current and future trends |
| Q38013789 | Allergen-specific immunotherapy: from therapeutic vaccines to prophylactic approaches. |
| Q36395501 | Allergy testing: the role of recombinant allergens |
| Q35873779 | Allergy vaccines--new approaches to an old concept |
| Q37625553 | An immunological overview of allergen specific immunotherapy -- subcutaneous and sublingual routes |
| Q51978305 | Antigens drive memory IgE responses in human allergy via the nasal mucosa. |
| Q35850656 | Biology of tree pollen allergens |
| Q52785931 | Candidin and trichophytin stimulate the production of Th1 and regulatory cytokines by peripheral blood mononuclear cells: implication for their use as adjuvants in immunotherapy. |
| Q39321330 | Carbohydrate-based particles reduce allergic inflammation in a mouse model for cat allergy. |
| Q37822834 | Clinical immunology review series: an approach to desensitization |
| Q42631175 | Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. |
| Q38761412 | Clinical use of adjuvants in allergen-immunotherapy. |
| Q52767099 | Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope-based grass pollen allergy vaccine with allergen extract-based vaccines. |
| Q56827917 | Cytokine and Antibody Responses in Birch-Pollen-Allergic Patients Treated with Genetically Modified Derivatives of the Major Birch Pollen Allergen Bet v 1 |
| Q36302500 | Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials |
| Q35566610 | Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy. |
| Q88289109 | Dust mite allergen-specific immunotherapy increases IL4 DNA methylation and induces Der p-specific T cell tolerance in children with allergic asthma |
| Q33733105 | Effect of activation of Toll-like receptor 7 in the inhibition of allergic asthma on a mouse model |
| Q35113146 | Effects of nasal corticosteroids on boosts of systemic allergen-specific IgE production induced by nasal allergen exposure |
| Q34051852 | Egg-white-specific IgA and IgA2 antibodies in egg-allergic children: is there a role in tolerance induction? |
| Q42578489 | Epicutaneous Immunotherapy for Aeroallergen and Food Allergy |
| Q34166561 | Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy |
| Q92701792 | Exopolysaccharide Produced by Lactobacillus paracasei IJH-SONE68 Prevents and Improves the Picryl Chloride-Induced Contact Dermatitis |
| Q39329667 | Expression of recombinant Ara h 6 in Pichia pastoris but not in Escherichia coli preserves allergic effector function and allows assessment of specific mutations. |
| Q37900649 | Factors influencing the allergenicity and adjuvanticity of allergens. |
| Q51042780 | Fast onset of action of sublingual immunotherapy in house dust mite-induced allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial. |
| Q58617547 | Flow-assisted quantification of in vitro activated basophils in the diagnosis of wasp venom allergy and follow-up of wasp venom immunotherapy |
| Q36549691 | Generation of hypoallergenic neoglycoconjugates for dendritic cell targeted vaccination: a novel tool for specific immunotherapy |
| Q37479670 | How safe are the biologicals in treating asthma and rhinitis? |
| Q28482224 | Identification of critical amino acids in an immunodominant IgE epitope of Pen c 13, a major allergen from Penicillium citrinum |
| Q50760318 | IgE+ B cells are scarce, but allergen-specific B cells with a memory phenotype circulate in patients with allergic rhinitis. |
| Q36545702 | IgE-mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy |
| Q33770788 | IgG antibodies produced during subcutaneous allergen immunotherapy mediate inhibition of basophil activation via a mechanism involving both FcgammaRIIA and FcgammaRIIB. |
| Q34484071 | Immune mechanisms of allergen-specific sublingual immunotherapy |
| Q38181015 | Immunobiology of critical pediatric asthma |
| Q38994739 | Immunoglobulin Glycosylation Effects in Allergy and Immunity |
| Q28265326 | Immunological mechanisms of allergen-specific immunotherapy |
| Q38352179 | Immunotherapy in all aspects |
| Q35671703 | Immunotherapy of allergic disease |
| Q73903596 | Induction of 'blocking' IgG antibodies during immunotherapy |
| Q46961929 | Inhibition of rBet v 1-induced basophil histamine release with specific immunotherapy -induced serum immunoglobulin G: no evidence that FcgammaRIIB signalling is important |
| Q40263989 | Inhibition of type I allergic responses with nanogram doses of replicon-based DNA vaccines. |
| Q52324318 | Innate Immune Responses in Leprosy. |
| Q41156645 | MPLA shows attenuated pro-inflammatory properties and diminished capacity to activate mast cells in comparison with LPS. |
| Q37502904 | Mechanisms of sublingual immunotherapy |
| Q37958561 | Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives |
| Q37309704 | Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy |
| Q52625055 | Microcrystalline Tyrosine and Aluminum as Adjuvants in Allergen-Specific Immunotherapy Protect from IgE-Mediated Reactivity in Mouse Models and Act Independently of Inflammasome and TLR Signaling. |
| Q36383819 | Molecular approaches for new vaccines against allergy |
| Q35558343 | Molecular evolution of hypoallergenic hybrid proteins for vaccination against grass pollen allergy. |
| Q26743503 | Monitoring Allergen Immunotherapy Effects by Microarray |
| Q40511372 | Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses. |
| Q33846653 | Nature of regulatory T cells in the context of allergic disease |
| Q26824787 | New strategies for allergen T cell epitope identification: going beyond IgE |
| Q47884083 | Next generation immunotherapy for tree pollen allergies |
| Q55436442 | Next-Generation of Allergen-Specific Immunotherapies: Molecular Approaches. |
| Q45102968 | Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. |
| Q39103046 | Novel approaches and perspectives in allergen immunotherapy |
| Q36901292 | Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides |
| Q37439440 | Optimized subunit vaccine protects against experimental leishmaniasis |
| Q36689005 | Pollinex Quattro: a novel and well-tolerated, ultra short-course allergy vaccine |
| Q44240760 | Pollinex Quattro: an innovative four injections immunotherapy in allergic rhinitis |
| Q42772049 | Possible therapeutic potential of a recombinant group 2 grass pollen allergen-specific antibody fragment. |
| Q98177685 | Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible? |
| Q79307565 | Production of interleukin-12 by monocytes and interferon-gamma by natural killer cells in allergic patients during rush immunotherapy |
| Q34430399 | Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy. |
| Q39366990 | Rational design of hypoallergens applied to the major cat allergen Fel d 1. |
| Q37847222 | Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens |
| Q39284149 | Recombinant allergy vaccines based on allergen-derived B cell epitopes. |
| Q34361546 | Recombinant house dust mite allergens. |
| Q38366518 | Review: The role of antibodies, autoantigens and food allergens in canine atopic dermatitis. |
| Q47649812 | Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32. |
| Q40790855 | Specific allergen immunotherapy: effect on IgE, IgG4 and chemokines in patients with allergic rhinitis |
| Q91218696 | Strong dose response after immunotherapy with PQ grass using conjunctival provocation testing |
| Q34787526 | Structural and immunologic cross-reactivity among filarial and mite tropomyosin: implications for the hygiene hypothesis |
| Q55527154 | Sub-lingual immunotherapy: world allergy organization position paper 2009. |
| Q48273752 | Subcutaneous immunotherapy with purified Der p1 and 2 suppresses type 2 immunity in a murine asthma model |
| Q37888684 | Subcutaneous versus sublingual immunotherapy for allergic rhinitis and/or asthma |
| Q36583727 | Sublingual immunotherapy of allergic diseases |
| Q35842681 | Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents |
| Q45417025 | The TLR4 agonist, monophosphoryl lipid A, attenuates the cytokine storm associated with respiratory syncytial virus vaccine-enhanced disease. |
| Q51581569 | The clinical significance of food specific IgE/IgG4 in food specific atopic dermatitis. |
| Q26801862 | The expanding role of immunopharmacology: IUPHAR Review 16 |
| Q37502385 | The influence of antigen targeting to sub-cellular compartments on the anti-allergic potential of a DNA vaccine |
| Q35146543 | The role of casein-specific IgA and TGF-β in children with food protein-induced enterocolitis syndrome to milk |
| Q35824051 | Therapeutics targeting the innate immune system |
| Q43988658 | Tolerogenic T cells, Th1/Th17 cytokines and TLR2/TLR4 expressing dendritic cells predominate the microenvironment within distinct oral mucosal sites |
| Q35975564 | Transition from a botanical to a molecular classification in tree pollen allergy: implications for diagnosis and therapy |
| Q83892585 | Ultra-short-course seasonal allergy vaccine (Pollinex Quattro) |
| Q26768511 | Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future |
| Q81453794 | [Immunologic control parameters during specific immunotherapy] |
Search more.